MedMira
Public Information
The Company planned to issue a Press Release with a commercial update this month. Due to a highly positive change in the commercial...
top of page
MedMira
- Jan 11
- 3 min
MedMira receives CE mark for its VYRA™ CoV2Flu Antigen Test
Halifax, Nova Scotia, 11 January, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of the CE mark for its VYRA™...
MedMira
- Jan 5
- 1 min
MedMira's G4 HIV (FDA approved) rapid test - an independent evaluation by the CDC
Performance Evaluation of the MedMira Reveal G4 LAB S/P and POC HIV Antibody Rapid Screening Tests using Plasma and Whole Blood Specimens...
MedMira
- Jan 3
- 4 min
Point-of-Care Diagnostic for Trichomonas vaginalis based on MedMira’s RVF Technology®
Halifax, Nova Scotia, 3 January, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the publication of Point-of-Care Diagnostic...
MedMira
- Jan 3
- 4 min
Point-of-Care Diagnostic for Trichomonas vaginalis based on MedMira’s RVF Technology®
Halifax, Nova Scotia, 3 January, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the publication of Point-of-Care Diagnostic...
MedMira
- Dec 29, 2022
- 3 min
MedMira Introduces VYRA TriDemic
Halifax, Nova Scotia, 29 December, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) presents its latest addition to the VYRATMproduct...
bottom of page